Many treatment guidelines for psoriasis rely heavily on body surface area (BSA) involvement to determine disease severity and eligibility for systemic therapies like biologics. Traditionally, patients with less than 10% BSA involvementespecially Real World Canadian Case Series: Use of Tildrakizumab for Moderate to Severe Psoriasis Peptides Lack Reliable Safety Information, Watchdog Warns Real World Canadian Case Series: Use of Tildrakizumab for Moderate to Severe Psoriasis Frontiers Promising strategies in natural products treatments of psoriasis update Psoriasis harbors multiple pathogenic type 17 T cell subsets: Selective modulation by risankizumab Journal of Allergy and Clinical Immunology